How many FDA warning letters has Naveh Pharma LTD/Bigdam Inc. received?

Argus HQ has recorded 1 FDA warning letter for Naveh Pharma LTD/Bigdam Inc..

What FDA recalls has Naveh Pharma LTD/Bigdam Inc. issued?

Argus HQ has not recorded an FDA recall tied to Naveh Pharma LTD/Bigdam Inc. in our current dataset.

Is Naveh Pharma LTD/Bigdam Inc. FDA compliant?

Argus HQ is not a compliance rating service. As of this page's last update, our dataset shows 1 warning letter, 0 recalls, and 0 approval records for Naveh Pharma LTD/Bigdam Inc.. Review the linked FDA source records directly before drawing a compliance conclusion.

.hq

company

Naveh Pharma LTD/Bigdam Inc.

Name: FDA Enforcement Actions Against Naveh Pharma LTD/Bigdam Inc.
Creator: Argus HQ
License: https://argushq.ai/methodology

Industry: pharmaceutical

Jurisdiction: US

FDA Warning Letter timeline

V1 scope: FDA Warning Letters only. Additional public-record sources (SEC, CPSC, federal contracts) are on the V2 roadmap and are not surfaced here today.

fda_warning_letter · cgmp2026-05-04
Naveh Pharma LTD/Bigdam Inc. — CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug (2026-05-04)

Frequently asked questions

How many FDA warning letters has Naveh Pharma LTD/Bigdam Inc. received?: Argus HQ has recorded 1 FDA warning letter for Naveh Pharma LTD/Bigdam Inc..
What FDA recalls has Naveh Pharma LTD/Bigdam Inc. issued?: Argus HQ has not recorded an FDA recall tied to Naveh Pharma LTD/Bigdam Inc. in our current dataset.
Is Naveh Pharma LTD/Bigdam Inc. FDA compliant?: Argus HQ is not a compliance rating service. As of this page's last update, our dataset shows 1 warning letter, 0 recalls, and 0 approval records for Naveh Pharma LTD/Bigdam Inc.. Review the linked FDA source records directly before drawing a compliance conclusion.

Informational only. FDA Warning Letters are public records (17 USC §105). Summaries are AI-assisted and may contain errors; always verify against the original FDA letter before acting. Not legal, financial, or regulatory advice.